Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients

NCT03179761 is registered in ClinicalTrials.gov with Vanderbilt-Ingram Cancer Center as lead sponsor.

NCT NCT03179761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03179761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients
Lead sponsor
Vanderbilt-Ingram Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
October 9, 2017
Completion date
October 1, 2024
Enrollment
124 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoietic cell transplantation